Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Tezspire / tezepelumab for treating severe asthma as of April 2023

MARA Rating Company December 16, 2025

Mounjaro / tirzepatide for treating type 2 diabetes as of October 2023

MARA Rating Company December 16, 2025

Mounjaro / tirzepatide for managing overweight and obesity as of December 2024

MARA Rating Company December 16, 2025

Kymriah / tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under as of May 2024

MARA Rating Company December 16, 2025

Evusheld / tixagevimab plus cilgavimab for preventing COVID-19 as of June 2023

MARA Rating Company December 16, 2025

Tofacitinib / xeljanz for treating active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis as of October 2021

MARA Rating Company December 16, 2025

Tofacitinib / xeljanz for treating active ankylosing spondylitis as of October 2023

MARA Rating Company December 16, 2025

Somapacitan for treating growth hormone deficiency in people 3 to 17 years as of June 2025

MARA Rating Company December 16, 2025

Somatrogon for treating growth disturbance in children and young people aged 3 years and over as of February 2023

MARA Rating Company December 16, 2025

Lumykras / sotorasib for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer as of March 2022

MARA Rating Company December 16, 2025